Complement Therapeutics received IND clearance from U.S. FDA today to start a trial of its AAV gene therapy for geographic atrophy that delivers a truncated version of Complement Receptor 1 to the eye

BiotechTV - News - Complement Therapeutics received IND clearance from U.S. FDA today to start a trial of its AAV gene therapy for geographic atrophy that delivers a truncated version of Complement Receptor 1 to the eye